Celldex in the News
- January 18, 2012Celldex Therapeutics to Host Research and Development Day Highlighting Oncology Pipeline
- January 17, 2012Celldex Therapeutics Announces Initiation of Phase 1 Clinical Trial of CDX-301
- January 4, 2012Celldex Initiates a Phase 2 Study of Rindopepimut in Patients with Recurrent Glioblastoma including Avastin® Naive and Refractory Populations
- December 21, 2011Celldex Completes Accrual of CDX-011 Phase 2b "EMERGE" Study in Advanced Breast Cancer
- December 12, 2011Celldex Therapeutics Presents Novel Preclinical Data on CDX-1127 at the American Society of Hematology Meeting in San Diego
- December 1, 2011Celldex Initiates ACT IV, a Pivotal International Phase 3 Trial of Rindopepimut in Patients with Glioblastoma
|
|
CNN Report |
|
|
BioBusiness.TV |
About Celldex
Celldex Therapeutics is the first antibody-based combination immunotherapy company. Celldex has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused Precision Targeted Immunotherapy Platform. The PTI Platform is a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators used in optimal combinations to create novel disease-specific drug candidates.
Precision Targeted Immunotherapy
 |
APC Targeting Technology™
Featured Links
- Celldex Research and Development Day - January 23, 2012
- ASH 2011 Poster - Development of a Human Anti-CD27 Antibody with Efficacy in Lymphoma and Leukemia Models by Two Distinct Mechanisms
- SNO 2011 Presentation - Long-term Follow-up of ACT III: A Phase 2 Trial of Rindopepimut (CDX-110) in Newly Diagnosed Glioblastoma presented by lead investigator Rose K. Lai, M.D.
- Cancer Immunotherapy Conference 2011 Presentation - Overview of Celldex’s Precision Targeted Immunotherapy Platform with a focus on rindopepimut (CDX-110) and critical factors in the validity of data for vaccines presented by Thomas Davis, M.D.
- AACR 2011 Poster- Anti-Tumor Activity of a Fully Human anti-CD27 Monoclonal Antibody in a Transgenic Mouse Model
- iSBTc 2010 Poster - Early Development of CDX-1401, A Novel Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205, in Combination with Toll-like Receptor Agonists
- ASCO 2010 Poster - Frequent Dosing and GPNMB Expression with CDX-011 (CR011-vcMMAE), an Antibody-Drug Conjugate (ADC), in Patients with Advanced Melanoma
- ASCO 2010 Poster - Correlation of GPNMB Expression with Outcome in Breast Cancer (BC) Patients Treated with the Antibody-Drug Conjugate (ADC), CDX-011 (CR011-vcMMAE)
- Learn more about APC Technology - Celldex's proprietary technology platform uses fully human monoclonal antibodies administered directly to patients to target and stimulate dendritic cells and macrophages.